User profiles for Takayuki Nakayama
nakayama takayuki大阪工業大学 Verified email at oit.ac.jp Cited by 425 |
[HTML][HTML] Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells
N Nakao, T Nakayama, T Yahata, Y Muguruma… - The American journal of …, 2010 - Elsevier
Mesenchymal stem cells (MSCs) have emerged as a new therapeutic modality for
reconstituting the hematopoietic microenvironment by improving engraftment in stem cell …
reconstituting the hematopoietic microenvironment by improving engraftment in stem cell …
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis
…, F Hakim, HK Kim, JE Janik, N Grant, T Nakayama… - Blood, 2005 - ashpublications.org
The occurrence of delayed neutropenia following rituximab is poorly defined and of unknown
cause. We hypothesized it may be related to perturbations of stromal derived factor-1 (SDF-…
cause. We hypothesized it may be related to perturbations of stromal derived factor-1 (SDF-…
[HTML][HTML] Mast cell–derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors
T Nakayama, L Yao, G Tosato - The Journal of clinical …, 2004 - Am Soc Clin Investig
Multiple myeloma in humans is frequently associated with mast cell infiltration and
neovascularization, which correlate directly with disease severity, but the mechanisms underlying …
neovascularization, which correlate directly with disease severity, but the mechanisms underlying …
Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells
T Nakayama, N Mutsuga, L Yao… - Journal of leukocyte …, 2006 - academic.oup.com
Mast cells (MCs) are common components of inflammatory infiltrates and a source of
proangiogenic factors. Inflammation is often accompanied by vascular changes. However, little is …
proangiogenic factors. Inflammation is often accompanied by vascular changes. However, little is …
Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome)
…, T Okamura, N Amemiya, T Nakayama… - Blood, The Journal …, 2001 - ashpublications.org
Macrothrombocytopenia with leukocyte inclusions is a rare autosomal dominant platelet
disorder characterized by a triad of giant platelets, thrombocytopenia, and characteristic Döhle …
disorder characterized by a triad of giant platelets, thrombocytopenia, and characteristic Döhle …
Stress augments insulin resistance and prothrombotic state: role of visceral adipose-derived monocyte chemoattractant protein-1
…, K Takeshita, K Yamamoto, R Kikuchi, T Nakayama… - Diabetes, 2012 - Am Diabetes Assoc
Stressors contribute to thrombosis and insulin resistance. Since obesity-related adipose
inflammation is also involved in these pathological states, we assumed that stress correlates …
inflammation is also involved in these pathological states, we assumed that stress correlates …
Angiotensin receptor blocker irbesartan reduces stress-induced intestinal inflammation via AT1a signaling and ACE2-dependent mechanism in mice
…, Y Uchida, K Yamamoto, T Nakayama… - Brain, behavior, and …, 2018 - Elsevier
Stress is associated with pathophysiology of both irritable bowel syndrome (IBS) and
hypertension. Angiotensin receptor blockers (ARB) have anti-inflammatory properties via inhibition …
hypertension. Angiotensin receptor blockers (ARB) have anti-inflammatory properties via inhibition …
[HTML][HTML] Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
…, R Kikuchi, M Shoaib Hamrah, T Nakayama… - Scientific reports, 2017 - nature.com
Chronic stress is closely linked to the metabolic syndrome, diabetes, hyperuricemia and
thromboembolism, but the mechanisms remain elusive. We reported recently that stress targets …
thromboembolism, but the mechanisms remain elusive. We reported recently that stress targets …
[HTML][HTML] Biomarkers for immune checkpoint inhibitors in melanoma
S Kitano, T Nakayama, M Yamashita - Frontiers in oncology, 2018 - frontiersin.org
Immune checkpoint inhibitors have now become a standard therapy for malignant melanoma.
However, as immunotherapies are effective in only a limited number of patients, biomarker …
However, as immunotherapies are effective in only a limited number of patients, biomarker …
[HTML][HTML] Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy
…, Y Horimoto, H Onagi, D Ikarashi, T Nakayama… - Breast Cancer …, 2021 - Springer
Background Tumour-infiltrating lymphocyte (TIL)-high breast tumours have a high rate of
pathological complete response (pCR) with neoadjuvant chemotherapy. In our routine …
pathological complete response (pCR) with neoadjuvant chemotherapy. In our routine …